www.deep-pharma.tech
info@deep-pharma.tech

# Cell Therapies in Healthcare Landscape Overview Q2 2021 Stem Cells and CAR-Ts (Teaser)

May 2021

DEEP PHARMA INTELLIGENCE

# Introduction

This teaser is highlighting key findings and content blocks for the 115-page report "**A Landscape of Cell Therapy Technologies in Healthcare 2021**" is the first systematic study of the cell therapy industry by Deep Pharma Intelligence, which serves as a landscape overview and a beginning of a series of reports and analytics studies related to the domain of cell therapies and regenerative medicine. This reports specifically focuses on Stem Cells and CAR-T therapies.

The main aim of this series of reports is to provide a comprehensive overview of the industry landscape in what pertains to adoption of stem cell technologies in drug discovery, clinical research, regenerative medicine, cosmetics and other applications. This overview highlights trends and insights in a form of informative mind maps and infographics as well as benchmarks the performance of key players that form the space and relations within the industry. This is an overview analysis to help the reader understand what is happening in the industry nowadays and possibly give an idea of what is coming next.

The reports is based on the online cloud-based analytics system (Dashboard), which incorporated the database of all entities featured in the report, and tens of thousands of data points about market trends, key developments, funding, deals, and more. While this report serves as an introduction into the industry, the underlying analytics system is updated on daily basis and can be a powerful tool for monitoring the fast-paced industry of stem cells, cell therapies, and regenerative medicine.
Alongside investment and business trends, the report also provides technical insights into some of the latest achievements in the stem cell research and practical medical and R&D applications.



# Stem Cells Introduction

**Stem cells (SCs)** are progenitors of all cell and tissue types in the body, they generate daughter somatic cells and have high potency for differentiation. Stem cells are able to activate different genetic patterns, it gives them the ability to produce a variety of daughter cells with many functions.

Gene activation potential, also called potency, separates stem cells in categories: totipotent (SCs that are able to differentiate into any type of other cells in an organism, e.g. – zygote), pluripotent (SCs that can produce intraembryonic cells, but not extraembryonic cells like those that form placenta), multipotent (SCs that can generate specific range of cells, e.g. – blood stem cells (hematopoietic) can produce erythrocytes, leukocytes, neutrophils etc.)







*Photos: Bisturmed, Science Direct*

# CAR-T Technology and Stem Cells Application in Immunotherapy







**Chimeric Antigen Receptors (CARs)** are artificially engineered receptors that give human T cells ability to recognize specific targets, e.g. cancer cells. In addition to target-recognizing characteristics CARs activate T cell cytotoxicity – ability to destroy aims via different methods like expression of soluble factors. To perform this procedure, patient's T cells are harvested from the blood, transformed in the laboratory setting to express CARs and infused back to a patient.

Due to the complexity of T cells collection in some groups of patients, immunoreactive answer to allogeneic CAR-T transplantants, latest developments propose to use patients autologous SCs and induce them into T cells with following genetic modifications. This approach potentially improves efficiency of CAR-T therapy in patients with low leukocyte levels and reduces rejection reactions like graft-vs-host disease.

*Photos: Cancer Research UK, CrownBio's Oncology Blog*

# Stem Cells: Analytics Framework

## Product Outlook

- Adult Stem Cells
  - Neuronal
  - Hematopoietic
  - Mesenchymal
  - Umbilical
  - Dental
  - Adipose-derived
  - Dedifferentiated fat cells (DFAT)
- Human Embryonic Cells
- Induced Pluripotent Stem Cells
- Very Small Embryonic Like Stem Cells
- Perinatal Stem Cells
- Other Product Types

## Regional Outlook

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Australia

## Therapy Outlook

- Allogeneic Stem Cells
- Autologic Stem Cells
- Syngeneic Stem Cells

## Technology Outlook

- Cell Production
  - Therapeutic Cloning
  - In-vitro Fertilization
  - Cell culture
  - Isolation
- Cell Acquisition
  - Bone Marrow Harvest
  - Umbilical Blood Cell
  - Apheresis
- Cryopreservation
- Expansion and Sub-Culture

## Application Outlook

- Regenerative medicine
  - Neurology
  - Orthopedics
  - Oncology
  - Hematology
  - Cardiovascular
  - Injures
  - Diabetes
  - Liver disorder
- Drug discovery and Development

DEEP PHARMA INTELLIGENCE

# Cell Therapies: Timeline of Key Events 2014 – 2021

**First Therapeutic Applications** — 2014-2015

- Breakthrough for manufacturing stem cells.
- First embryonic stem cells cloned from a man's skin.
- First patient received experimental stem cell treatment for age-related macular degeneration.

**Genetics & Stroke Treatment** — 2016-2017

- First Human Embryos Edited in U.S. using CRISPR Technique.
- Stem cells reported to provide substantial recovery in patients disabled by stroke.

**Bioprinting & Cancer Treatment** — 2018

- First 3D-printed cornea made from algae and human stem cells.
- Mouse and human skin cells reprogrammed into immune cells to fight cancer.

**Development of Immunotherapies** — 2019

- Second patient reported free of HIV after receiving stem-cell therapy.
- Gene therapy shown to be promising in treating infants born with X-linked severe combined immunodeficiency (SCID-X1).

**New Stem Cells Discovered** — 2020-2021

- New type of pluripotent stem cell isolated from mice, horses, and humans, named XPSCs, which are capable of generating chimeras and germ cell precursors.

# Cell Therapies in Healthcare Landscape Overview Q2 2021 (Stem Cells and CAR-T)

Companies - 400
Investors - 200
Corporations - 15




DEEP PHARMA INTELLIGENCE

# Application of Cell Therapies in Pharma R&D and Medicine (Stem Cells and CAR-Ts)

**Companies - 400**




DEEP PHARMA INTELLIGENCE

# Analysis of Top 50 Cell Therapy Companies: R&D Maturity vs Application Focus



# Comparison of Top 50 Cell Therapy Companies: R&D Maturity vs Funding Level



# Cell Therapy Companies: Regional Proportion




The US is still in the lead in terms of its proportion of cell therapy companies. Interestingly, Asia Pacific region currently has almost the same proportion of cell therapy companies as Europe. However, Asia-Pacific region has begun to aggressively increase its activity in the space in terms of investments into foreign companies (largely US-based companies), and we expect to see an increase in the number of cell therapy companies located in the Asia-Pacific region generally, and in China particularly.

# Public Vs Private Cell Therapy Companies




- Public Companies – 130
- Private Companies – 250
- Delisted Companies – 10
- No Information – 10

## 5 Notable Public Companies

- ExoCoBio
- Allogene Therapeutics
- Fate Therapeutics
- bluebird bio
- Neon Therapeutics

## 5 Notable Private Companies

- BioNTech
- CARsgen Therapeutics
- Tmunity Therapeutics
- eGenesis
- Obsidian Therapeutics

# Market Cap of Public Cell Therapy Companies in Million US$ (NASDAQ)



# 20 New Players in Cell Therapy Industry (2018 - 2020)

| | | | |
|---|---|---|---|
| 2020 | Be Biopharma | 2018 | Ambys Medicines |
| 2020 | BlueSphere Bio | 2018 | Bioinova |
| 2020 | Catamaran Bio | 2018 | Century Therapeutics |
| 2020 | Innoskel | 2018 | CytoMed Therapeutics Pte Ltd |
| 2020 | Sonoma BioTherapeutics | 2018 | Cytonus Therapeutics |
| 2019 | Antleron | 2018 | Emmecell |
| 2019 | Arsenal Biosciences | 2018 | Instil Bio |
| 2019 | Artiva Biotherapeutics | 2018 | Kyverna Therapeutics |
| 2019 | Cellares | 2018 | Medisix Therapeutics Pte Ltd |
| 2019 | Luminary Therapeutics | 2018 | Neogene Therapeutics |

# Application of Cell Therapies (Stem Cells and CAR-T) in Pharma R&D and Medicine

# Application of Cell Therapies (Stem Cells and CAR-T) in Pharma R&D and Medicine










# FDA Approved Stem Cell & CAR-T Therapies

| Company | Cell Therapy Name | Indication | Year of Initial US Approval | Type of Cell Therapy |
|---|---|---|---|---|
| Bristol Myers Squibb | Lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | 2021 | CAR-T |
| Kite Pharma | Tecartus (brexucabtagene autoleucel) | Relapsed or refractory mantle cell lymphoma | 2020 | CAR-T |
| Novartis | Kymriah (tisagenlecleucel) | Acute lymphoblastic leukemia | 2017 | CAR-T |
| Kite Pharma | Yescarta (axicabtagene ciloleucel) | Non-Hodgkin lymphoma | 2017 | CAR-T |
| SSM Cardinal Glennon Children's Medical Center | Allocord (Hpc, Cord Blood) | Hematopoietic disorders | 2012 | Stem Cell Therapy |
| Cleveland Cord Blood Center | Clevecord (Hpc Cord Blood) | Hematopoietic disorders | 2016 | Stem Cell Therapy |
| Duke University School of Medicine | Ducord (Hpc Cord Blood) | Hematopoietic disorders | 2012 | Stem Cell Therapy |
| Organogenesis Incorporated | Gintuit | Mucogingival conditions | 2012 | Stem Cell Therapy |
| New York Blood Center, Inc | Hemacord | Hematopoietic disorders | 2019 | Stem Cell Therapy |
| Clinimmune Labs, University of Colorado Cord Blood Bank | HPC, Cord Blood | Hematopoietic disorders | 2012 | Stem Cell Therapy |

# FDA Approved Stem Cell & CAR-T Therapies

| Company | Cell Therapy Name | Indication | Year of Initial US Approval | Type of Cell Therapy |
|---|---|---|---|---|
| Md Anderson Cord Blood Bank | Hpc, Cord Blood – Md Anderson Cord Blood Bank | Hematopoietic Disorders | 2018 | Stem Cell Therapy |
| Lifesouth Community Blood Centers, Inc. | Hpc, Cord Blood–lifesouth Community Blood Centers, Inc | Hematopoietic Disorders | 2013 | Stem Cell Therapy |
| Bloodworks | Hpc, Cord Blood – Bloodworks | Hematopoietic Disorders | 2016 | Stem Cell Therapy |
| Biovex, Subsidiary Of Amgen | Imlygic (Talimogene Laherparepvec) | Melanoma | 2015 | Stem Cell Therapy |
| Fibrocall Technologies | Laviv (Azficel-t) | Nasolabial Fold Wrinkles | 2011 | Stem Cell Therapy |
| Spark Therapeutics | Luxturna | Leber Congenital Amaurosis | 2017 | Stem Cell Therapy |
| Vericel | Maci (Autologous Cultured Chondrocytes On A Porcine Collagen Membrane) | Cartilage Injuries | 2019 | Stem Cell Therapy |
| Dendreon Corp | Provenge (Sipuleucel-t) | Prostate Cancer | 2010 | Stem Cell Therapy |
| Avexis | Zolgensma (Onasemnogene Abeparvovec-xioi) | Spinal Muscular Atrophy | 2019 | Stem Cell Therapy |

# Cell Therapies: Research Statistics

The overall preclinical and clinical research landscape in cell therapies industry is highly reliant on the fundamental research and advances in certain enabling technologies, such as genetic reprogramming, CRISPR-Cas9, sequencing technologies, delivery technologies, mass cell culturing methods, stem cell production (generation of iPSCs) and many others.
The industry is characterized by a high risk-high reward dynamics, where ongoing breakthroughs can substantially change the business landscape, by disrupting legacy approaches and protocols.
There is also a substantial growth potential, once certain technological questions are addressed, for instance, identification of new targets for the CAR-T, which would allow expanding applications from purely liquid cancers, to also solid tumors.



| | CLINICAL TRIALS | PUBLICATIONS | GRANTS FUNDING | PATENTS |
|---|---|---|---|---|
| 2017 | 422 | 17508 | $2,2 Billion | 6304 |
| 2018 | 423 | 17490 | $2,3 Billion | 6340 |
| 2019 | 476 | 17497 | $2,5 Billion | 7500 |
| 2020 | 526 | 13083 | $2,2 Billion | 7719 |

# Investment Landscape at a Glance (2020 — 2021)

## Some of the major deals included:

- **JW Therapeutics** raised **$300 million** on IPO in Hong Kong Stock Exchange, bringing new CAR-T immunotechnology to China.
- **CARsgen Therapeutics** pulled off **$180 million** in Series C investment round. The company attracted 5 investors, with a lead investor Loyal Valley Capital.
- **Legend Biotech** received a funding of **$150 million** over one Series A round in April 2020. Following that, Legend Biotech went on IPO in June 2020.
- **Poseida Therapeutics** has raised a total of **$110 million** during Series D round in June 2020.
- **Gracell Biotechnologies** attracted 7 investors in Series C funding with a total investment of **$100 million**.

## Notable Investment Deals in 2020 ( in million US$)



# Leading Companies by Amount and Stage of Funding



# Leading Companies by Amount and Stage of Funding



# Leading Companies by Amount and Stage of Funding



# Cell Therapy Investors in US

## United States

### Menlo Park

- Menlo Ventures — Menlo Park, California, US
- Astellas Venture Management — Menlo Park, California, US
- 5AM Ventures — Menlo Park, California, US
- Sofinnova Investments — Menlo Park, California, US
- Canaan Partners — Menlo Park, California, US
- Kleiner Perkins — Menlo Park, California, US
- Khosla Ventures — Menlo Park, California, US

### San Francisco

- Redmile Group — San Francisco, California, US
- Amgen Ventures — San Francisco, California, US
- EcoR1 Capital — San Francisco, California, US
- Alexandria Venture — San Francisco, California, US
- VenBio Partners — San Francisco, California, US
- Alta Partners — San Francisco, California, US
- CIRM — San Francisco, California, US

### Massachusetts

- Atlas Venture — Cambridge, Massachusetts, US
- Polaris Partners — Boston, Massachusetts, US
- Flagship Pioneering — Cambridge, Massachusetts, US
- Third Rock Ventures — Boston, Massachusetts, US
- Fidelity — Cambridge, Massachusetts, US
- RA Capital Management — Boston, Massachusetts, US
- Adage Capital Management — Boston, Massachusetts, US

### New York

- Cormorant Capital — New York, New York, US
- OrbiMed — New York, New York, US
- Invus — New York, New York, US
- Aisling Capital — New York, New York, US
- Casdin Capital — New York, New York, US

### Illinois

- Deerfield Capital Management — Rosamond, Illinois, US
- ARCH Venture Partners — Chicago, Illinois, US
- Tactics II Stem Cell Ventures — Northbrook, Illinois, US

### Palo Alto

- Venrock — Palo Alto, California, US
- Vivo Capital — Palo Alto, California, US

### California

- Thiel Capital — Los Angeles, California, US
- Domain Associates — San Diego, California, US
- Sanderling Ventures — San Mateo, California, US
- Illumina Ventures — Foster City, California, US

# Cell Therapy Investors in Europe & Asia

## Europe

### UK

- **Syncona Partners LLP**
  London, England, United Kingdom
- **4BIO Capital**
  London, England, United Kingdom
- **AlbionVC**
  London, England, United Kingdom
- **Arthurian Life Sciences**
  London, England, United Kingdom
- **Cancer Research Technology**
  London, England, United Kingdom
- **Eight Roads Ventures**
  London, England, United Kingdom
- **Innovate UK**
  Swindon, Wiltshire, United Kingdom

### Germany

- **Bayer**
  Leverkusen, Germany
- **Fresenius Medical Care**
  Bad Homburg, Hessen, Germany
- **TVM Capital**
  Munich, Bayern, Germany
- **Wellington Partners**
  Munich, Bayern, Germany

### Belgium

- **S.R.I.W.**
  Liège, Liege, Belgium

### Spain

- **Grifols**
  Barcelona, Catalonia, Spain
- **Suma Venture**
  Barcelona, Catalonia, Spain

### Switzerland

- **Novartis**
  Basel, Basel-Stadt, Switzerland
- **HBM Healthcare Investments**
  Zug, Zug, Switzerland
- **Nextech Invest**
  Zurich, Zurich, Switzerland

## Asia

### Japan

- **Kyoto-iCAP**
  Kyoto, Kyoto, Japan
- **Mitsubishi UFJ Capital**
  Tokyo, Japan

### China

- **IDG Capital**
  Beijing, China
- **Sequoia Capital**
  Beijing, China
- **Morningside Group**
  Shanghai, China
- **Lilly Asia Ventures**
  Shanghai, China

# Top 20 Strategic Investors in Cell Therapy Industry

| Pharma Companies Investors | Cell Therapy Companies | | | | |
|---|---|---|---|---|---|
| Takeda | catamaranBIO | ARCELLX | | be BIOPHARMA | OBSIDIAN THERAPEUTICS |
| | Adicet Bio | | gamida cell | | Intellia THERAPEUTICS |
| J&J INNOVATION | Adicet Bio | VOR BIOPHARMA | LEGEND BIOTECH | | |
| GILEAD | | TMUNITY™ | | | |
| BAYER | | egenesis ENGINEERING LIFE | | | |
| FOSUNPHARMA 复星医药 | FOSUNKite 复星凯特生物 | | | | |
| | KYTOPEN | | | | |
| SHANGHAI PHARMA INNOVATION | OBSIDIAN THERAPEUTICS | | | | |
| Pfizer | NexImmune | | | | |
| SANOFI | Fate THERAPEUTICS | | | | |

# Conclusions

With more than 100.000 research publications and above 1000 clinical trials taking place globally, the area of cell therapies research (stem cell and CAR-T) is steadily expanding in terms of new knowledge and understanding of fundamental biological processes associated with production and application of stem cells, CAR-T technologies, and other cell therapies in general. The area is characterized by a steady flow of scientific breakthroughs with high translational potential, which opens up a landscape of opportunities for prospective investors.

However, notwithstanding of substantial amount of clinical data showing relative safety and efficacy of cell therapies, related to stem cells and CAR-T, the overall presence of commercially available medical products and services is still rather limited, which is reflective of the fact that the market is in early days of development -- with substantial growth potential overall. Up to now, only 5 CAR-T therapies has been approved by FDA, including Abecma by Bluebird Bio and Bristol Myers Squibb, Tecartus™ by Kite Pharma, and others, as well as 19 Stem Cell products -- all being blood-forming stem cells (also known as hematopoietic progenitor cells) that are derived from umbilical cord blood. These products are approved for use in patients with disorders that affect the production of blood.

| CAR-T cell | Brand name | Company | Targeted disease |
|---|---|---|---|
| **Tisagenlecleucel** | Kymriah | Novartis | B-cell acute lymphoblastic leukemia, Diffuse Large B-cell lymphoma |
| **Axicabtagene Ciloleucel** | Yescarta | Kite Pharma / Gilead | DLBCL, Follicular lymphoma |
| **Brexucabtagene Autoleucel** | Tecartus | Kite Pharma / Gilead | Mantle Cell Lymphoma |
| **Lisocabtagene Maraleucel** | Breyanzi | Juno Therapeutics / BMS | DLBCL |
| **Idecabtagene Vicleucel** | Abecma | Bluebird Bio / BMS | Multiple myeloma |

# Conclusions

The current global landscape of leading cell therapy-focused companies, reviewed in this report, is represented by around 400 players, of which above 30% are public companies – the industry is largely unconsolidated and is still in early stage of maturity. Leading pharmaceutical players are actively involved in the cell therapies market with the aim of diversifying their existing research pipelines and trying to win the race in the emerging biotech competition -- this is reflected increasing activity in terms of internal programs, as well as R&D partnerships and direct investments into smaller biotechs, focused on stem cells and CAR-Ts.

**US is still a main player in stem cells industry,** accounting for the largest share of companies (more than 60%), both in R&D-stage clinical stage, and medical applications of stem cells of all companies in this sector globally. The stem cells sector is characterized by a growing activity in the venture capital investment landscape, which is reflected in the overall growth of investments in 2020 vs previous years. **Asian region is increasingly entering the global cell therapy market,** accounting for around 8% of all companies, with 2/3rds of them being in China. Europe and UK account for around 20% of all companies, around 1/4rd of them located in UK.



# Key Takeaways

While the area of stem cells and CAR-T technologies possesses disruptive potential in terms of the impact on the future of healthcare, the current value proposition is still extremely limited to patients due to a number of technological limitations, the overall high cost, and logistical complexities of applying such cell therapies and related treatments in practise. This is rapidly changing with a variety of ongoing technology improvements, and we expect rapid increase in FDA approvals and commercial products over the course of 5 years.

While the scope of applications for Stem Cells is wide, we believe that the most significant impact of this technology can be achieved in the field of treatment of neurodegenerative diseases, including Parkinson, Alzheimer's disease, and Multiple Sclerosis. Considering the absence of any meaningful progress with the current scope of treatments and research successes available in tackling the increasing the problem of neurological decline in eldergly population, latests research and early results associated with stem cells give hope for change.

The market of cell therapies is currently a growing opportunity for the private and institutional investors, and we expect the acceleration of funding inflow into the segments of stem cells and CAR-T technologies in the upcoming 2-5 years. Especially interesting opportunities emerge when companies develop specialized R&D platforms, capable of producing results with a wide variety of products and therapeutics areas.



# Key Takeaways

While the overall market of stem cells is experiencing a cautious optimism of investors, due to a number of setbacks in the past, the area of CAR-T technologies is increasingly attractive due to the large number of practical validations and success stories. There are, however, apparent limitations for the CAR-T technologies, which are currently limited to treating liquid forms of cancer, including lymphomas, leukosis.

We expect significant and widespread market growth once the problem of targeting solid tumours with CAR-T technologies is solved conceptually -- which might be related to identification of specific antigens, other than CD19. Once the technology is applicable to treatments of tumor cells, it will be targeting a much larger market and substantially wider range of applications.

A substantial market of stem cells applications is in the non-therapeutic applications, such as creating drug discovery models, 3D-bioprinting, regenerative medicine, industrial biotechnology, and other areas.



# About Deep Pharma Intelligence

**Deep Pharma Intelligence** is producing regular analytical reports on major areas of high-potential in the pharmaceutical and healthcare industries, maintaining ratings of companies and governments based on their innovation potential and business activity in the BioTech space, and providing strategic consulting and investment analytics services to top-tier clients, including major investment funds and banks, family offices, insurance companies, government organizations, and big pharma companies among others. The company is a joint venture between the two highly specialized UK-based market intelligence hubs in Pharma / BioTech space:

DEEP KNOWLEDGE ANALYTICS

**Pharma Division of Deep Knowledge Analytics** (PD-DKA), a specialized subsidiary of Deep Knowledge Analytics (DKA), the leading analytical entity specifically focused on deep intelligence of the high-potential areas in the pharma industry, including artificial intelligence (AI) for drug discovery sector.

Deep Knowledge Analytics Pharma Division serves as the main source of investment intelligence and analytics for AI-Pharma, a specialized index hedge fund for the AI in the drug discovery sector. PD-DKA's insights are frequently covered by top media such as Forbes and the Financial Times, and are acknowledged by top pharma executives.

Recently, MIT named this division a top technology think-tank, acknowledging the AI ranking framework it developed.

Bio Pharma Trend

**BPT Analytics (BiopharmaTrend)** - a rapidly growing analytical portal and media resource, dedicated to tracking emerging companies (startups/scaleups), innovations, investments, and trends in the pharma and biotech space.

BiopharmaTrend's reports and articles were referenced by Deloitte, Forbes, and other high profile media and consulting companies.

BiopharmaTrend is a media partner to a number of top-tier conferences and symposia in preclinical and clinical research, and healthcare research.

# Overview of Proprietary Analytics by Pharma Division of Deep Pharma Intelligence

**Deep Pharma Intelligence (DPI)** is a strategic partner to the leading Life Science organizations, investment institutions (VC funds, investment banks), and governments worldwide – in matters related to investments, strategic positioning, and policy development in the areas of pharmaceutical and biotech research, and healthcare tech.

While DPI is regularly producing open industry reports, covering high-growth sectors, including artificial intelligence, digital health, new therapies, more in-depth research is only available to our clients and strategic partners under the "Proprietary Analytics" category.

Our range of proprietary services includes custom consulting projects, based on the specific customer needs, a collection of pre-produced "ready-to-use" proprietary reports, covering general trends and specific action ideas and strategy insights related to the most promising investment prospects (e.g. new technologies, biotech startups), M&A prospects (e.g. pipeline development targets), and strategic growth ideas (trends profiling, industry overviews etc).

## Services:

- Investment landscape profiling, identifying investment ideas in the biotech/healthcare tech space.
- Preliminary due-diligence (business, science and technology, intellectual property (IP) profiling, freedom of operation assessment, legal assessment etc).
- Comprehensive due-diligence (deep business, science and technology assessment, IP and legal assessment, growth potential assessment etc).
- Infringement analysis of technology (i.g. If you plan to partner or invest in a data-analytics biotechs, or AI-development vendors, it is essential to understand their technological assets, both in terms of innovation potential and in terms of legal protection and non-infringement risk management).
- SWOT analysis of companies and technological sectors, competitive profiling.
- Industry profiling and growth strategy development for top-tier companies and governments.

# Overview of Proprietary Analytics by Pharma Division of Deep Pharma Intelligence

**Proprietary Reports**

There are a few 40+ page reports delivering practical answers to these specific questions in order to optimize the short and long-term strategies of biopharma corporations and other institutions related to the industry, with a newly updated edition being released each quarter, incrementally increasing the precision, practicality and actionability of its technological and financial analysis.

Our reports are supported by our rapidly developing data mining engine, data visualization platform and analytics dashboards.

## The value our reports can deliver:

- Deep analysis of the deal-making prospects in the biotech and healthcare tech space, identification of top mini-trends and larger tendencies in innovations and technology adoption (e.g. AI, blockchain, eHealth tech, longevity biomarkers, new therapeutics and therapies etc.);
- Tangible forecasts on the 3-5 years horizon, providing an overview of future scenarios of the development of various technologies in the pharma industry;
- Practical guides for adopting various technological solutions and best practises, vendor profiling and contract research strategy building;
- Analysis of key market players in the emerging and high-growth areas of the pharmaceutical and biotech industries.

The parties who gain early access to these reports will have deep expertise on how their strategic agendas can be optimized in order to leverage novel research, new technologies, and emerging market opportunities, and stay competitive in a rapidly-changing technological environment, and taking into account shifting global priorities and trends.

# Deep Pharma Intelligence: Upcoming Projects and Analytical Tools








## 3D Visualization Prototypes





## Visit Our Deep Pharma Intelligence Big Data Analytics Dashboard
## platform.dkv.global/p/dpi/stem-cells/

DEEP
PHARMA
INTELLIGENCE



**Link to the Report: https://www.deep-pharma.tech/cell-therapies**


**E-mail: info@deep-pharma.tech** | **Website: deep-pharma.tech**